The ESMO Congress is a highly influential oncology platform for clinicians,
researchers, patient advocates, journalists and healthcare industry
representatives from all over the world. https://www.esmo.org/
Several projects in which we collaborated were presented in October in
Madrid:
POSTERS
Acupuncture in patients (pts) with digestive cancer and
oxaliplatin-induced peripheral neuropathy (OIPN): Results of the ACUPOX phase
II GERCOR G-114 study
Authors
Emmanuelle
Kempf (Creteil, France) Bouras Amina (Créteil, France) Patricia Walleck (Paris,
France) Carolina Saldana (Creteil, France) Charlotte Fenioux (Creteil, France)
Helene Boussion (Paris, France) Eida Bui (Paris, France) Isabelle Cojean-Zelek
(Créteil, France) Anne Rohan (Paris, France) Olivier Caliez (Creteil, France)
Jean-Baptiste Bachet (Paris, France) Tam Nhan (Bobigny, France) Eliane Tang
(Nanterre, France) Camille Herve (Grenoble, France) Yves Delplanque (Grenoble,
France) Cyril Boisson (Besancon, France) Dewi Vernerey
(Besancon, France) Marie Line Garcia Larnicol (Paris, France)
Christophe Tournigand (Creteil, France, CEDEX) Philippe Jeannin (Paris, France)
Optimizing 1st-line NALIRIFOX
and Exploring the Role of Microbiota in 2nd-line Pancreatic Cancer Treatment:
The PRODIGE 105 GERCOR PANORAMIX study
Authors
Cindy Neuzillet (Boulogne-Billancourt, France)
Matthieu Delaye (Paris, France) Marc Hilmi (New York, United States of America)
Paul Gougis (Paris, France) Brice Chanez (Marseille, France) Gael Roth (La
Tronche, France) Victoire De Lastours (Clichy, France) Victoire Ruffino (Paris,
France) Marie Line Garcia Larnicol (Paris, France) Jean-Baptiste Bachet (Paris,
France) Dewi Vernerey (Besancon, France)
Trifluridine/tipiracil and
bevacizumab in refractory metastatic colorectal cancer patients : An AGEO
prospective multicenter real-world study
Authors
Flavie Soumagne (Paris, France) Anais Jenvrin (Paris,
France) Isabelle Trouilloud (Paris, France) Antoine Falcoz (Besancon,
France) Alice Boileve (Villejuif, France) Jerome Desrame (Lyon, France,
CEDEX 8) Jean-Baptiste Bachet (Paris, France) Laurent Mineur (Avignon, France,
CEDEX 2) Anthony Turpin (Lille, France) Debora Basile (Crotone, Italy) Olivier
Dubreuil (Paris, France) Marie Muller (Nancy, France) Lysiane Marthey (Le
Kremlin-Bicêtre, France) Romain Desgrippes (Saint Malo, France) Gael Goujon
(Paris, France) Matthieu Delaye (Paris, France) Anna Pellat (Paris, France)
Ronaldo Elkaddoum (Paris, France) David Tougeron (Poitiers, France, CEDEX)
Julien Taieb (Paris, France)
Beyond clinical risk:
Real-world insights from genomic profiling in early breast cancer – the
FREDO-ODX study
Authors
Elsa Curtit (Besancon, France) Marc-Antoine Benderra
(Paris, France) Julie Henriques (Besancon, France) Sandra Assoun
(Paris, France) Claire Giraud Genouville (Dechy, France) Fatima MENIAI
(Beauvais, France) Cristian Villanueva (Montpellier, France) Sylvain Ladoire
(Dijon, France, Cedex) Aurelie Fadin (Reims, France) Alexandre M. Henni (Arras,
France) Jean-Baptiste AISENFARB (Dunkerque, France) Caroline Bailleux (Nice,
France) Fernando Bazan (Clermont-Ferrand, France) Alice Pham Becker (Lens,
France, Pas de Calais) Emmanuelle Jacquet (La Tronche, France) Anne-Catherine
Degrendel (Dunkerque, France) Dorothee Chocteau (Nantes, France) Dewi
Vernerey (Besancon, France) Joseph Gligorov (Paris, France)
Eric-Charles Antoine (Neuilly-sur-Seine, France)
First-line (L1) durvalumab
with chemotherapy (D+CT) in advanced biliary tract cancer (aBTC): A
retrospective DIVA sub-study of the French ACABi PRONOBIL GERCOR cohort
Authors
Matthieu Delaye (Paris, France) Julie Henriques
(Besancon, France) Christophe Tournigand (Creteil, France, CEDEX) Alice
Boileve (Villejuif, France) Thomas Walter (Lyon, France) Sylvain Manfredi
(Dijon, France, CEDEX) Anthony Turpin (Lille, France) Gael Roth (La Tronche,
France) Thierry Lecomte (Chambray-lès-Tours, France) Jean-Baptiste Bachet (Paris,
France) Elia Gigante (Reims, France) Romain Desgrippes (Saint Malo, France)
Eric Assenat (Montpellier, France, CEDEX 5) Faiza Khemissa Akouz (Perpignan,
France) Jean-charles Nault (Bobigny, France) Laurent Costes (Créteil, France)
Marie Line Garcia Larnicol (Paris, France) Dewi Vernerey (Besancon,
France) Cindy Neuzillet (Boulogne-Billancourt, France) Julien Edeline
(Rennes, France, CEDEX)
Early changes in body composition independently predict
survival in patients (Pts) receiving immunotherapy for biliary tract cancers
(BTC): An ancillary study of the IMMUNO-BIL PRODIGE 57 GERCOR trial
Authors
Matthieu Delaye
(Paris, France) Anna Dordonnat (Creteil, France) Frédéric Pigneur (Paris,
France) Antoine Falcoz (Besancon, France) Eric Assenat
(Montpellier, France, CEDEX 5) Laetitia Dahan (Marseille, France) Jean Frédéric
Blanc (Bordeaux, France) David Tougeron (Poitiers, France, CEDEX) Jean-Philippe
Metges (Brest, France) Astrid Lievre (Rennes, France) Meher Ben Abdelghani
(Strasbourg, France) Clelia Coutzac (Lyon, France) Nadim Fares (Toulouse,
France) Anthony Turpin (Lille, France) Marie Line Garcia Larnicol (Paris,
France) Victoire Ruffino (Paris, France) Dewi Vernerey (Besancon, France)
Cindy Neuzillet (Boulogne-Billancourt, France) Marc Hilmi (New York,
United States of America)
Rapid ORAL Communication
Watch-and-wait (W&W)
strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal
adenocarcinoma (GEA): Results from the first interim analysis of the
GERCOR-GONO DEWI phase II study
Authors
Thierry André (Paris, France, CEDEX 12) Alessandra
Raimondi (Milan, Italy) Dewi Vernerey (Besancon, France) Denis
Smith (Pessac, France) Jean-Philippe Metges (Brest, France) David Tougeron
(Poitiers, France, CEDEX) Guillaume Piessen (Lille, France) Antoine Adenis
(Montpellier, France) Sabina Murgioni (Padua, Italy) Christelle De la
Fouchardiere (Marseille, France, CEDEX) Christophe Tournigand (Creteil, France,
CEDEX) Emilie Soularue (Paris, France) Clelia Coutzac (Lyon, France) Jérémie
Lefevre (Paris, France) Florence Renaud (Paris, France) Marine Camus (Paris,
France) Julie Henriques (Besancon, France) Marie Line Garcia Larnicol
(Paris, France) Filippo Pietrantonio (Milan, Italy)

About Sophie PAGET-BAILLY
Sophie Paget-Bailly is a research engineer in epidemiology and clinical research. She passed with honours the East of France inter-region master’s degree in public health and occupational and environmental risks. During the master’s degree’s internship in the Interregional Epidemiology Unit of Bourgogne/Franche-Comté, she realized a quantitative health risk assessment in the context of chemical contamination of groundwater. She defended a PhD in Public Health and Epidemiology in Paris XI University, Doctoral School 420, working in the Centre for Research in Epidemiology and Population Health in Villejuif, France. Her PhD research focused on occupational exposures and head and neck cancer.